Immunome (IMNM) Stock Forecast & Price Target

Compare

385 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMNM Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Immunome

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMNM Stock 12 Month Forecast

Average Price Target

$32.55

▲(63.16% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $32.55 with a high forecast of $40.00 and a low forecast of $21.00. The average price target represents a 63.16% change from the last price of $19.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.32,19.987692307692306,21.655384615384616,23.323076923076922,24.99076923076923,26.658461538461538,28.326153846153844,29.993846153846153,31.661538461538463,33.32923076923077,34.996923076923075,36.66461538461539,38.332307692307694,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.32,19.414615384615384,20.50923076923077,21.603846153846153,22.698461538461537,23.79307692307692,24.887692307692305,25.982307692307693,27.076923076923073,28.17153846153846,29.26615384615384,30.36076923076923,31.455384615384613,{"y":32.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.32,18.526153846153846,18.732307692307693,18.93846153846154,19.144615384615385,19.35076923076923,19.556923076923077,19.763076923076923,19.96923076923077,20.175384615384615,20.38153846153846,20.587692307692308,20.793846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$32.55

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Cory Kasimov

Evercore ISI

$18→$40

Buy

100.50%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Novan (NASDAQ: NOVN) and Adagene (NASDAQ: ADAG)

Adam Vogel

Craig-Hallum

$33

Buy

65.41%

Upside

Reiterated

12/16/25

Craig-Hallum Remains a Buy on Immunome (IMNM)

Chad Messer

Lake Street

$32

Buy

60.40%

Upside

Reiterated

12/16/25

Immunome price target raised to $32 from $22 at Lake StreetImmunome price target raised to $32 from $22 at Lake Street

Karina Rabayeva

Truist Financial

$36

Buy

80.45%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Viridian Therapeutics (NASDAQ: VRDN) and OmniAb (NASDAQ: OABI)

Michael Schmidt

Guggenheim

$25→$35

Buy

75.44%

Upside

Reiterated

12/15/25

Guggenheim Remains a Buy on Immunome (IMNM)

Andrew Berens

Leerink Partners

$40

Buy

100.50%

Upside

Reiterated

12/15/25

Immunome's Promising Outlook: Buy Rating Affirmed on Varegacestat's Phase 3 Success and Strong Management

Charles Zhu

LifeSci Capital

$20→$40

Buy

100.50%

Upside

Reiterated

12/15/25

Immunome's Varegacestat Shines in Phase 3 RINGSIDE Trial, Earning Buy Rating from Charles Zhu

Brian Cheng

J.P. Morgan

$22

Buy

10.28%

Upside

Reiterated

11/30/25

Analysts Offer Insights on Healthcare Companies: BrightSpring Health Services, Inc. (NASDAQ: BTSG) and Immunome (NASDAQ: IMNM)

Sudan Loganathan

Stephens

$25→$33

Buy

65.41%

Upside

Reiterated

11/17/25

Immunome price target raised to $33 from $25 at StephensImmunome price target raised to $33 from $25 at Stephens

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/11/25

Immunome's Strategic Clinical Advancements and Financial Alignment Justify Buy Rating

Biren Amin

Piper Sandler

$21

Buy

5.26%

Upside

Reiterated

11/07/25

Immunome (IMNM) Receives a Buy from Piper Sandler

Salveen Richter

Goldman Sachs

$26

Buy

30.33%

Upside

Initiated

09/22/25

Immunome's Promising Oncology Pipeline and Strong Market Potential Justify Buy Rating

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$21

Buy

5.26%

Upside

Reiterated

08/07/25

Wedbush Keeps Their Buy Rating on Immunome (IMNM)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$21

Buy

5.26%

Upside

Reiterated

08/01/25

Wedbush Reaffirms Their Buy Rating on Immunome (IMNM)

Jason Kolbert

D. Boral Capital

Hold

―

Downgraded

05/19/25

D. Boral Capital downgrades Immunome Inc. (IMNM) to Hold Pending Financial ClarityD. Boral Capital analyst Jason Kolbert downgraded Immunome Inc. (NASDAQ: IMNM) from Buy to Hold.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Cory Kasimov

Evercore ISI

$18→$40

Buy

100.50%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Novan (NASDAQ: NOVN) and Adagene (NASDAQ: ADAG)

Adam Vogel

Craig-Hallum

$33

Buy

65.41%

Upside

Reiterated

12/16/25

Craig-Hallum Remains a Buy on Immunome (IMNM)

Chad Messer

Lake Street

$32

Buy

60.40%

Upside

Reiterated

12/16/25

Immunome price target raised to $32 from $22 at Lake StreetImmunome price target raised to $32 from $22 at Lake Street

Karina Rabayeva

Truist Financial

$36

Buy

80.45%

Upside

Reiterated

12/16/25

Analysts Offer Insights on Healthcare Companies: Immunome (NASDAQ: IMNM), Viridian Therapeutics (NASDAQ: VRDN) and OmniAb (NASDAQ: OABI)

Michael Schmidt

Guggenheim

$25→$35

Buy

75.44%

Upside

Reiterated

12/15/25

Guggenheim Remains a Buy on Immunome (IMNM)

Andrew Berens

Leerink Partners

$40

Buy

100.50%

Upside

Reiterated

12/15/25

Immunome's Promising Outlook: Buy Rating Affirmed on Varegacestat's Phase 3 Success and Strong Management

Charles Zhu

LifeSci Capital

$20→$40

Buy

100.50%

Upside

Reiterated

12/15/25

Immunome's Varegacestat Shines in Phase 3 RINGSIDE Trial, Earning Buy Rating from Charles Zhu

Brian Cheng

J.P. Morgan

$22

Buy

10.28%

Upside

Reiterated

11/30/25

Analysts Offer Insights on Healthcare Companies: BrightSpring Health Services, Inc. (NASDAQ: BTSG) and Immunome (NASDAQ: IMNM)

Sudan Loganathan

Stephens

$25→$33

Buy

65.41%

Upside

Reiterated

11/17/25

Immunome price target raised to $33 from $25 at StephensImmunome price target raised to $33 from $25 at Stephens

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

11/11/25

Immunome's Strategic Clinical Advancements and Financial Alignment Justify Buy Rating

Biren Amin

Piper Sandler

$21

Buy

5.26%

Upside

Reiterated

11/07/25

Immunome (IMNM) Receives a Buy from Piper Sandler

Salveen Richter

Goldman Sachs

$26

Buy

30.33%

Upside

Initiated

09/22/25

Immunome's Promising Oncology Pipeline and Strong Market Potential Justify Buy Rating

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$21

Buy

5.26%

Upside

Reiterated

08/07/25

Wedbush Keeps Their Buy Rating on Immunome (IMNM)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$21

Buy

5.26%

Upside

Reiterated

08/01/25

Wedbush Reaffirms Their Buy Rating on Immunome (IMNM)

Jason Kolbert

D. Boral Capital

Hold

―

Downgraded

05/19/25

D. Boral Capital downgrades Immunome Inc. (IMNM) to Hold Pending Financial ClarityD. Boral Capital analyst Jason Kolbert downgraded Immunome Inc. (NASDAQ: IMNM) from Buy to Hold.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunome

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+9.92%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.92% per trade.

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+23.28%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +23.28% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

5/6 ratings generated profit

Average Return

+70.47%

reiterated a buy rating 5 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +70.47% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+76.22%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +76.22% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMNM Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMNM has received 21 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. IMNM average Analyst price target in the past 3 months is 32.55.

Each month's total comprises the sum of three months' worth of ratings.

IMNM Financial Forecast

IMNM Earnings Forecast

Next quarter’s earnings estimate for IMNM is -$0.58 with a range of -$0.75 to -$0.21. The previous quarter’s EPS was -$0.65. IMNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.

IMNM Sales Forecast

Next quarter’s sales forecast for IMNM is $956.00K with a range of $0.00 to $4.10M. The previous quarter’s sales results were $0.00. IMNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.

IMNM Stock Forecast FAQ

What is IMNM’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunome’s 12-month average price target is 32.55.

What is IMNM’s upside potential, based on the analysts’ average price target?

Immunome has 63.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMNM a Buy, Sell or Hold?

Immunome has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Immunome’s price target?

The average price target for Immunome is 32.55. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $21.00. The average price target represents 63.16% Increase from the current price of $19.95.

What do analysts say about Immunome?

Immunome’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of IMNM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Immunome (IMNM) Stock Forecast & Price Target

IMNM Analyst Ratings

IMNM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunome

IMNM Analyst Recommendation Trends

IMNM Financial Forecast

IMNM Earnings Forecast

IMNM Sales Forecast

IMNM Stock Forecast FAQ

Detailed List of Analyst Forecasts